SCHEMBL3763291

SCHEMBL3763291

Fc1cccc(-c2csc(Br)n2)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 4/20 0.50
HSD17B10 Q99714 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
VCP P55072 1/20 0.39
AR P10275 2/20 0.39
EIF4E P06730 1/20 0.38
TRPA1 O75762 1/20 0.38
GSTO1 P78417 1/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
GRM5 P41594 1/20 0.36
CCNE2 O96020 1/20 0.35
CCNE1 P24864 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775075 0.85 MPL (0.68) MPLHSD17B10NPC1RAB9AALDH1A1
SCHEMBL474677 0.82 MPL (0.74) MPLHSD17B10NPC1RAB9AALDH1A1
SCHEMBL13002992 0.81 MPL (0.49) MPLNPC1RAB9AALDH1A1GAA
SCHEMBL22261467 0.74 PIK3R1 (0.36) MPLSMN1; SMN2PIK3R1PIK3CACCNE2
SCHEMBL30172683 0.74 PIK3R1 (0.36) MPLSMN1; SMN2PIK3R1PIK3CACCNE2
SCHEMBL3038641 0.73 CES2 (0.46) MPLNPC1PIK3R1PIK3CACCNE2
SCHEMBL27928104 0.73 SCN9A (0.41) MPLNPC1RAB9ASMN1; SMN2TDP1
SCHEMBL3766189 0.71 HTR2C (0.48) MPLHSD17B10NPC1RAB9AALDH1A1
SCHEMBL4077757 0.71 MPL (0.46) MPLHSD17B10NPC1RAB9AALDH1A1
SCHEMBL3766113 0.71 MAOA (0.51) MPLNPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 MPL 2916/4885HSD17B10 853/4885NPC1 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.